This conference call transcript was computer generated and almost certianly contains errors. This transcript is provided for information purposes only.EarningsCall, LLC makes no representation about the accuracy of the aforementioned transcript, and you are cautioned not to place undue reliance on the information provided by the transcript.
9/15/2022
Celeste, Life Sciences Investor Symposium on GPS. At this time, all participants are in a listen-only mode. If anyone should require operator assistance during the conference, please press star zero on your telephone keypad. Please note this conference is being recorded. I would now like to turn the conference over to Allison Sauce, Investor Relations. Thank you. You may begin.
Thank you. Good afternoon, everyone. I am Allison Sauce from KCSA Strategic Communications. and it is my pleasure to welcome you to the Pellis Investor Symposium on Gallup Express for GPS. For those of you who have dialed in rather than joining by webcast, I would like to remind you that there are presentation slides accompanying this call. To view the slides, please join the webcast, which is available on the Investor Relations section of Pellis' website, as well as in the event press release. Next, I would like to remind you that Pellis will be making forward-looking statements Such forward-looking statements can be identified by the use of the words expect, believe, will, anticipate, estimate, plan, project, and other words of similar import. The forward-looking statements in the presentation include, they're not limited to statements related to the potential commercial opportunity for our clinical candidate, GPS. These forward-looking statements are based on current plans, objectives, estimates, expectations, and intentions, and inherently involve significant risks and uncertainties. Actual results and the timing of events could differ materially from those anticipated in such forward-looking statements as a result of these risks and uncertainties, which include without limitation risks and uncertainties associated with the COVID-19 pandemic and its impact on the company's clinical plans and business strategy, immunology product development and clinical success thereof, the uncertainty of regulatory approval, and other risks and uncertainties affecting CELUS and its development programs. These risks and uncertainties are described more fully under the caption risk factors in CELUS's annual report on Form 10-K filed on March 31, 2022, and in its other filings with the Securities and Exchange Commission. Other risks and uncertainties of which CELUS is not currently aware, may also affect CELUS's forward-looking statements. The forward-looking statements herein are made only as of the date hereof. CELUS undertakes no obligation to update or supplement any forward-looking statements to reflect actual results, new information, future events, changes in its expectations, or other circumstances that exist after the date as of which the forward-looking statements were made. All statements in this presentation assume a statistically significant and clinically meaningful data outcome from the phase three re-roll study for GPS, a successful BLA filing with the FDA and marketing approval by the FDA. The key topic of today's symposium is Bellis' lead clinical asset, GPS, and its pathway to commercialization. Dr. Angela Sergio, the company's president and chief executive officer, will begin today's program with some remarks around today's event, and then introduce our speaker, Robert Franco-Mano, Fellowship's Chief Commercial Officer. With that, I will now hand the call over to Angelo.
Good afternoon, everyone, and welcome to our second investor symposium on our lead asset, Galimpepe Modesto GPS. First, thank you for your participation and support in joining today's virtual symposium. We are very excited to take this time to focus on GPS to discuss the commercial opportunity ahead. We will highlight the significant unmet need in acute myeloid leukemia and why CELUS is well-placed to leverage its early mover status to develop effective treatments for this patient group. At CELUS, as you know, our core mission is to develop and deliver innovative treatments for patients battling cancer and prolong patients' lives. We believe that GPS has the potential to be a game-changing treatment for leukemia patients and other WT1-expressing tumors. CELAS is proud of the progress we've made so far in developing GPS with several key milestones achieved this year alone. However, we believe now is a pivotal time in the assets development as we prepare for commercialization. It is for that reason that we wanted to hold this call at this point is an update of the roadmap to commercialization for GPS. We recently reported clinical benefits seen in preliminary data from our Phase I-II clinical trial of GPS in combination with a checkpoint inhibitor, Keytruda, in patients battling WT1-positive advanced ovarian cancer. We also released encouraging updated clinical data from a Phase I investigator-sponsored clinical trial of GPS in combination with another checkpoint inhibitor, Opdivo, in patients with malignant pleural mesothelioma. In our phase three regal study, we continued enrolling patients and activating additional sites across the United States, Europe, and Asia. CELAS has established a very productive and strong collaborative relationship with 3D medicines, our partner in China. In March, An IND application for a small phase one clinical trial investigating safety was approved by China's National Medical Products Administration. The approval triggered a milestone payment of $1 million, which we received earlier this year, and 3D Medicines expects to initiate the trial by mid-2022. 3D Medicine's current clinical development plan provides for initiation of a Phase II clinical trial following receipt of satisfactory safety data from the Phase I clinical trial. The initiation of the Phase II clinical trial will trigger a significant milestone payment to sellers. We're also currently investigating the opportunity for 3D Medicine to join the Regal Study as our study partner in China, and we will update you around that accordingly. In March, we announced an exclusive license agreement that grants rights to CELUS for the development and commercialization of GFH-009, a highly selective CDK9 inhibitor across all therapeutic and diagnostic users worldwide outside of greater China. This was an exciting development for CELUS as we expanded our clinical pipeline. CDK9 activity has been shown to negatively correlate with overall survival in a number of cancer types, including hematologic cancers such as AML and lymphomas, as well as solid cancers. We were pleased to acquire GFH009, and we believe it possesses complementary opportunities for our current GPS pipeline, as well as allowing us to enter into different tumor types including pediatric soft tissue sarcomas. Concurrent with the in-license of GFH009 in March, we closed the public offering with gross proceeds of $25 million with key institutional life science investors and underwritten by SVB Lyrinc and Cantor Fitzgerald. The funds provide us with additional runway as we prepare to achieve several pipeline milestones. We were pleased to secure this funding despite the challenging market conditions that the year has presented, but it has positioned us to continue to execute on our strategic priorities amid the current market volatility in the biotech sector. Now, the main reason we're all here to learn more about the commercialization opportunity ahead for GPS. It is my pleasure to introduce the best person to unveil the work that has already begun to prepare for commercialization Celeste's Chief Commercial Officer, Robert Franco-Mano. Robert joined Celeste in March of this year. He's a highly seasoned executive with over two decades of biopharmaceutical commercial leadership. His track record includes building and managing oncology product brands through all stages of commercialization and transforming a company from clinical stage to full commercialization. Robert has hit the ground running at Celeste and we're very excited to have him update the investment community. With that, I will now hand the call over to Robert Franco-Mano.
You're reading a preview of the SLS Q2 2022 earnings call.
Free account.
